CatalystMarker
← board

AAWH

distress 2/10 · well-funded / low risk
$0.43+2%today-60% from 52w high
awholdings.com2,300 employeesFounded 2018Rochelle Park, NJDrug Manufacturers - Specialty & Generic
Revenue
$117M
Liquidity
$61M
Runway
Shares 1y

Price & events

-33.1% over 6M
$0.41$0.55$0.69Jan 26Apr 26Jul 261.0Mdilution: EFFECT shelf_effective (2026-01-22)
CatalystRating changeDilutionFinancingdashed = today
+1.9%
1D
-2.9%
1W
-13.0%
1M
-23.3%
3M
-33.1%
6M
+8.6%
1Y
-54.5%
2Y
-95.9%
5Y
-95.5%
All

Overview

Market Cap
$86.87M
Enterprise Value
$318.26M
Volume
54.10K
52 Week Range
$0.35 – $1.08
Total Shares
202.97M
Float Shares
139.92M
% Held by Insiders
20.29%
% Held by Institutions
11.43%
RVOL
1.34x
Beta
1.76

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 202,973,284 · 0 offerings/1y · 0 PIPEs
  • 2026-01-22EFFECTshelf_effective
  • 2025-12-19S-3shelf_registration
  • 2025-01-148-Kmaterial_agreement
  • 2024-07-228-Kmaterial_agreement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.